TipRanks
Go Ultimate55% OFF

Manulife Financial (MLU) AI Stock Analysis

DE:MLU

Manulife Financial

(Frankfurt:MLU)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Broad insurance growth and stronger future earnings backlogDouble-digit APE growth across Asia, Canada and the U.S., alongside rising CSM measures, indicates broad demand and a larger stock of future contractual earnings. This supports revenue visibility beyond one reporting period.
Negative Factors
Insurance claims and investment spread pressureUnfavorable claims and expense experience in Canada, combined with U.S. claims and spread pressure, can weigh on insurance margins. Persistent adverse experience would limit the conversion of sales growth into durable earnings.

Manulife Financial (MLU) vs. iShares MSCI Germany ETF (EWG)

-10%0%10%20%30%40%50%DE:MLU+47.45%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 74.05B
Dividend Yield
2.89%
Average Volume (3M)
108
Price to Earnings (P/E)
16.8
Beta (1Y)
0.44
Revenue Growth
11.47%
EPS Growth
12.07%
Country
Germany
Employees
37,000
Sector
General
Sector Strength
55
Industry
Insurance - Life

Manulife Financial Business Overview & Revenue Model

Company Description

Manulife Financial Corporation is a global provider of financial products and services, operating across Asia, Canada, the United States, and other international regions. Its business is structured into three main segments: Wealth and Asset Managemen...

Manulife Financial Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:9.48%|Next Earnings Date:Nov 03, 2026
Earnings Call SentimentPositive

The call highlighted multiple strong operating and financial results — double-digit APE growth across segments, meaningful improvements in new business metrics and core EPS, robust capital ratios (LICAT 136%) and strategic execution including an innovative LTC biometric risk transfer and AI leadership. Headwinds include unfavorable insurance experience in Canada and some U.S. life spread/ALDA pressure, targeted outflows in parts of Global WAM, and elevated central expenses. Management presented these challenges as manageable with mitigating actions (claims management, repricing ability, continued capital generation and targeted investments). Overall, the positives around growth, profitability, capital strength and risk-reduction transactions materially outweigh the contained negatives.

Positive Updates

Strong APE Sales Growth Across Segments
Total APE sales grew 21% year-over-year with double-digit growth across all insurance segments: Asia +21%, Canada +23%, U.S. +12%. APE sales per active agent increased over 30% YoY.

Negative Updates

Canada Insurance Experience and Earnings Pressure
Canada core earnings declined 10% YoY, driven by unfavorable claims and expense experience in group insurance and normal claims variability in individual insurance; management expects Canada insurance experience to trend to neutral by year-end but elevated transformation expenses will persist.

Company Guidance

The company reiterated its medium‑term/2027 guidance and capital priorities: an 18%+ core ROE ambition (Q2 core ROE 16.3%, +130 bps YoY), a 2.5% ongoing share‑buyback program, and on‑track 2027 remittances, supported by strong capital and leverage metrics (LICAT 136%, ≈$26B excess of supervisory target; financial leverage 22.2% vs. 25% medium‑term target). Management expects Canada insurance experience to trend to neutral by year‑end, corporate results to be a loss of $300–$400M (likely toward the high end), and an expense‑efficiency medium‑term target below 45% (44.5%); operating and growth metrics cited include APE sales +21% YoY (Asia +21%, Hong Kong +37%, Canada +23%, U.S. +12%), new business CSM +16% YoY, CSM balance +20%, Global WAM net inflows $0.4B, core EPS +16% (core earnings +12% YoY; Asia core earnings +21%; Global WAM core earnings +9%), adjusted book value per share $41.12 (+15% YoY), core EBITDA margin 31.2% (+110 bps), and details on the LTC transaction ($3.2B of reserves at 80% quota share, ~−5% IFRS cede / ~6–7% NAIC cede, CAD 30M foregone core earnings in year 1), which reduces LTC morbidity risk by 24% while current LTC claim savings exceed 6% and the retained block is expected to start generating capital over the next 5–10 years.

Manulife Financial Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:MLU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:FFHTSE:FFH83OutperformCAD 55.98B8.4616.94%0.83%-1.15%1.30%
TSE:GWOTSE:GWO81OutperformCAD 82.51B18.9015.48%2.84%4.29%21.91%
TSE:IFCTSE:IFC78OutperformCAD 45.96B14.4615.73%2.20%3.25%38.09%
TSE:POWTSE:POW76OutperformCAD 60.26B23.5010.91%2.71%9.74%-3.94%
TSE:SLFTSE:SLF76OutperformCAD 62.93B19.0813.89%3.32%-0.59%5.22%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%20%40%60%DE:MLUTSE:SLFTSE:FFHTSE:GWOTSE:IFCTSE:POWDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:MLU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:MLUManulife Financial40.3713.3449.35%
TSE:SLFSun Life Financial113.1730.7637.33%
TSE:FFHFairfax Financial Holdings Ltd2501.52280.8612.65%
TSE:GWOGreat-West Lifeco92.2434.8160.60%
TSE:IFCIntact Financial260.632.841.10%
TSE:POWPower Corp Of Canada96.6032.4850.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.